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Abstract
Malarone® (atovaquone-proguanil) is an effective drug for the treatment and prophylaxis of
multidrug-resistant falciparum malaria. However, first cases of resistance have been reported,
which are associated with mutations at codon 268 of the parasite's cytochrome b gene. We report
the first case of Malarone® treatment failure from Central Africa.
Drug concentration was well within curative range. Pre- and post-treatment Plasmodium falciparum
isolates revealed codon 268 wild-type alleles, and no other mutations of the putative atovaquone-
binding domain.
These findings illustrate the spread of atovaquone-proguanil-resistance in Africa and question the
usefulness of codon 268 as the only target for the surveillance of its emergence.
Introduction
Resistance to antimalarial drugs poses an increasingly seri-
ous problem to public health worldwide. Since the late
1990s, the combination of atovaquone and proguanil is
commercially available as a fixed antimalarial compound
(Malarone®; GlaxoSmithKline). It is well tolerated and
effective against multidrug-resistant Plasmodium falci-
parum  isolates. Both atovaquone and proguanil have
causal prophylactic activity against the hepatic stages of P.
falciparum which enables prophylaxis to be stopped seven
days after leaving a malaria-endemic area. For these rea-
sons, Malarone is a frequently used prophylactic agent
especially in short-term travellers [1].
In malaria parasites, atovaquone inhibits mitochondrial
electron transport at the level of the cytochrome bc1 com-
plex and collapses the electropotential across the mito-
chondrial inner membrane [2]. Atovaquone as a single
agent is associated with high recrudescence rates, but the
combination with proguanil resulted in cure rates close to
100%. However, the probability of selecting for
atovaquone-proguanil-resistant mutants has been esti-
mated as one in 500 treatments [3].
Non-immune travellers who import malaria parasites into
non-endemic countries are a suitable group for the sur-
veillance of antimalarial drug-resistance. The first case of
Malarone®  resistance in Africa occurred in a traveller
returning from Nigeria [4]. Analysis of the cytochrome b
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gene revealed a point mutation at codon 268 (Tyr-
268→Asn). For East Africa, the first case of confirmed
Malarone® resistance was observed in a non-immune trav-
eller to Kenya. That patient's isolate also revealed a muta-
tion at codon 268, but tyrosine changed to serine (Tyr-
268→Ser) [5]. These two codon 268 variants are within
the region encoding the putative atovaquone-binding
domain. This is the only genetic change in the parasite to-
date which has been associated with Malarone® treatment
failure in vivo. Therefore, these mutations are considered
useful tools for the surveillance of resistance to Malarone®
[6,7].
Case report
The case of a thirty-eight year old Congolese woman, a
resident in Germany for 12 years, who returned from a
four-week stay in Kinshasa with fever, chills, headache
and myalgia, is reported. It was her first trip to Africa since
she had settled in Germany and she took chloroquine for
chemoprophylaxis. Blood smear examination revealed P.
falciparum at a parasite density of 0.1% and an antigen
capture test (Mala Quick, R-Biopharm, Germany) con-
firmed P. falciparum mono-infection.
The patient received a directly observed standard treat-
ment course of Malarone® for three days, four tablets daily
(one tablet is equivalent to 250 mg of atovaquone and
100 mg of proguanil hydrochloride). Tablets were taken
with food and were well tolerated. No vomiting or diar-
rhoea occurred during hospitalization. High performance
liquid chromatography (Shimatzu, Japan) on Day 2 of
treatment confirmed a drug concentration of atovaquone
above the required therapeutic plasma concentration
(17.2  µg/mL) which excludes impaired bioavailability.
Symptoms resolved and parasites were cleared after three
days. Sixteen days after discharge from hospital, the
patient presented at our clinic with fatigue and headache
but no fever. A blood smear demonstrated once again P.
falciparum mono-infection at an asexual parasite density
of 0.01%. Re-treatment with a 6-dose regime of co-arte-
mether (20 mg artemether and 120 mg lumefantrine) was
successful.
For further analysis, the pre-treatment and the resistant P.
falciparum isolates were investigated for point mutations
of cytochrome b codon 268 by nested PCR and enzymatic
restriction digest as recently described [6]. Analysis
revealed wild-type alleles in both isolates. A 716 bp frag-
ment of the cytochrome b gene containing the encoding
region of the putative atovaquone-binding domain was
amplified [7]. Sequencing (ABI, Applied Biosystem, MWG
Biotech Ebersberg, Germany) revealed the absence of all
mutations previously described to be involved in
atovaquone-resistance in vivo and in vitro [8], no further
variants were found.
Discussion
So far, investigations on Malarone resistance supported
the association with the cytochrome b codon 268 muta-
tions. In contrast, the late treatment failure in our patient
in the absence of above described mutations suggests that
other mechanisms might also be involved. The sympto-
matic reappearance of malaria parasites after therapy
despite initial adequate drug concentrations confirms
clinical resistance to this drug.
Recently, another case of Malarone® treatment failure not
associated with cytochrome b mutations has been reported
[9], in which parasites were not cleared on Day 2 of the
treatment course. Therapy was changed to mefloquine
and parasites were cleared on Day 4; Day 3 parasite counts
were not presented. Considering the comparatively slow
onset of parasite clearance following Malarone® treatment
[10], the definition as an early treatment failure seems
questionable in that case.
Conclusion
The value of cytochrome b codon 268 as a single molecular
marker for the surveillance of Malarone® resistance should
be reconsidered in the light of this finding. Further
research is required for a better understanding of the
mechanisms involved in the development of resistance to
Malarone®, one of the few available drugs for multidrug-
resistant falciparum malaria.
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